bluebird bio: The Appealing Decision to Separate its Severe Genetic Disease and Oncology Businesses into Independent Publicly-Traded Firms

bluebird bio Decision to Separate its Businesses
bluebird bio (BLUE) will retain focus on its severe genetic disease (SGD) and will launch its oncology business (Oncology Newco) as a new entity. The Board of Directors at bluebird bio approved this decision and it is anticipated that the spin-out of Oncology Newco is to be tax-free . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.